All In Biotech

Drug Trial Radar · NCT05092360

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

Last checked: Nov 19, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 456 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

456

Actual

Start

Jan 10, 2022

Primary completion

Jan 8, 2025

Study completion May 8, 2025

Sponsor

Lead sponsor
Mural Oncology, IncIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Conditions

  • Platinum-resistant Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Interventions

  • Nemvaleukin and Pembrolizumab CombinationBiological

    Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes

  • PembrolizumabBiological

    Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes

  • NemvaleukinBiological

    Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes

  • Pegylated Liposomal Doxorubicin (PLD)Drug

    40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)

  • PaclitaxelDrug

    80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min

  • TopotecanDrug

    4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min

  • GemcitabineDrug

    1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From the first dose of study drug up to 24 months

Locations

117 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Arizona Oncology

    Tucson, Arizona

  • University of California, San Diego (UCSD)- Moores Cancer Center

    La Jolla, California

  • University of California, Los Angeles (UCLA)

    Los Angeles, California

  • Ventura County Hematology- Oncology

    Oxnard, California

  • University of Florida (UF) Health Cancer Center - Orlando Health

    Orlando, Florida

  • Sarasota Memorial Hospital

    Sarasota, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Indiana University (IU)

    Indianapolis, Indiana

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Trinity Health Ann Arbor Hospital

    Ypsilanti, Michigan

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • University of New Mexico

    Albuquerque, New Mexico

  • Womens Cancer Care Associates

    Albany, New York

  • Westchester Medical Center

    Hawthorne, New York

  • NYU Langone Health

    New York, New York

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York

  • Vidant Medical Center

    Greenville, North Carolina

  • University of Cincinnati (UC) - Cancer Institute

    Cincinnati, Ohio

  • The Ohio State University (OSU)

    Columbus, Ohio

  • Mid Ohio Oncology/Hematology, Inc. dba The Mark H. Zangmeister Center

    Columbus, Ohio

  • Williamette Valley Cancer Institute and Research Center

    Eugene, Oregon

  • Providence Portland Medical Center

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • Texas Oncology - Austin Central (Balcones Dr.)

    Austin, Texas

  • Texas Oncology - DFWW (Bedford)

    Bedford, Texas

  • Texas Oncology - Fort Worth Cancer Center

    Fort Worth, Texas

  • Baylor College of Medicine

    Houston, Texas

  • University of Virginia - Emily Couric Cancer Center

    Charlottesville, Virginia

  • Virginia Cancer Specialists, PC (Lake Manassas Dr)

    Gainesville, Virginia

  • Cancer Research SA

    Adelaide, Australia

  • Blacktown Hospital

    Blacktown, Australia

  • Royal Brisbane and Women's Hospital

    Brisbane, Australia

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.